Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 3, 2008

Vermillion Inks Exclusive License for Stanford University’s PAD Biomarker Panel

  • Stanford University granted Vermillion exclusive rights to the biomarker panel related to peripheral artery disease (PAD). Stanford and Vermillion have already completed a 540-patient clinical study evaluating the ability of the biomarker panel to classify individuals into high and low risk groups for PAD.

    Based on these results, the company plans to further develop the panel for risk assessment. Vermillion will commercialize a blood test utilizing the multimarker panel to stratify an individual’s danger for developing the disease.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »